INDEPENDENT STUDY OF OVARIAN CANCER CTCS HARVESTED BY THE PARSORTIX SYSTEM HIGHLIGHTS POTENTIAL TO PREDICT PROGRESSION FREE SURVIVAL FOR DRUG TRIALS The study investigated 123 metastatic ovarian ...
Parsortix platform shown to be compatible with the Roche BenchMark ULTRA automated staining system, with initial study of three key drug targets: HER2 (breast), TROP2 (lung) and PSMA (prostate) Roche ...
Indivior Plc presents results from the phase 3 pivotal study of RBP-6000 buprenorphine monthly depot
* Indivior Plc - 24-week study met its primary and key secondary endpoints for both dosage regimens of RBP-6000 * Indivior - Clinical data from phase 3 study also showed outcomes with RBP-6000 are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback